



MEDICAL PRODUCT ALERT

DRAP ALERT NO. N° I/S/01-25-02

RECALL NOTICES ISSUED BY PROVINCIAL DRUG TESTING LABORATORIES.

Date: 02nd January, 2025

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses).
- General Public.

Alert Summary:

DDCP PV Lahore has informed DRAP regarding recall of following batches of mentioned products:

S#	Product Name	Batch No.	Manufactured by	Test Results
1	Rasmic suspension 60ml (Mefenamic acid 50mg/5ml) Reg# 032405	4H099	Rasco Pharma 5.5Km, Raiwind road, Lahore	Contains Ethylene Glycol (EG) 2.19% that is above permissible limits.
2	Resfyl cough syrup 60ml (Acefylling Piperzine 45mg, Diphenhydramine HCl 8mg) Reg# 057214	4A009	Rasco Pharma 5.5Km, Raiwind road, Lahore	Contains Ethylene Glycol (EG) 1.676 % that is above permissible limits.
3	Neocobal Injection 1ml (Mecobalamin 0.5mg/ml) Reg# 071447	S-2214	Pulse Pharmaceuticals (Pvt.) Ltd., Sua Aasil, Raiwind road, Lahore	Substandard & Adulterated
4	Safemed infusion 100ml (Metronidazole 500mg/100ml) Reg# 045824	S-790	Ahad International Pharmaceuticals Ltd., 13Km Gomal University, Multan Road, Dera Ismail Khan	Substandard

Action initiated: -

The regulatory field force of DRAP and Provincial Drug Control departments have been requested to immediately conduct market surveys for detection and removal of these products from the market.

Advice for Healthcare Professionals: -

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of these products are to be reported to the National



DRAP, Islamabad



+92 051 9255969



gsms@dra.gov.pk



Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this [link](#). Further information of reporting problems to DRAP is available on this [link](#).

Advice for Consumers / general public: -

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.



Drug Regulatory Authority of Pakistan

محفوظ، مونثر اور معيارى اشياءے علاج



DRAP, Islamabad



+92 051 9255969



gsms@dra.gov.pk